Format

Send to

Choose Destination
Am J Ophthalmol. 2018 Nov;195:43-62. doi: 10.1016/j.ajo.2018.07.024. Epub 2018 Jul 30.

Long-term Outcomes of Globe-Preserving Surgery With Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland.

Author information

1
David Glendenning Cogan Ophthalmic Pathology Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and the Harvard Medical School, Boston, Massachusetts, USA.
2
David Glendenning Cogan Ophthalmic Pathology Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and the Harvard Medical School, Boston, Massachusetts, USA. Electronic address: Fred_Jakobiec@meei.harvard.edu.
3
Biostatistics Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
4
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and the Harvard Medical School, Boston, Massachusetts, USA; Sutula Eye Associates, Milton, Massachusetts, USA.

Abstract

PURPOSE:

To describe outcomes of globe-preserving surgery combined with high-dose proton beam radiation (PBR) in treating primary adenoid cystic carcinoma (ACC) of the lacrimal gland.

DESIGN:

Retrospective case series.

METHODS:

Twenty-nine patients with primary ACC of the lacrimal gland were identified in the records of a single institution between 1990 and 2017. Patients with nonorbital primary tumor origins or with inadequate follow-ups were excluded. Eighteen patients met inclusion criteria. Clinical data, imaging studies, histopathology, treatment modality, local recurrences, visual outcomes, metastases, and survivals were assessed. Disease-free survivals for the current patients were measured and compared to those of other studies.

RESULTS:

The eighteen patients (14 female, 4 male) were followed for a median of 12.9 years (range 0.6-22.3 years) after treatment completion. Their median age was 40 years. Four were children (median age 12 years). All were treated with globe-preserving tumor resection and radiation (median dose of 72 cobalt gray equivalents). Three adult patients died of metastatic disease (median of 4.2 years after treatment). Four had local recurrences. Useful vision (20/40 or better) was retained for a median 3 years (range 1-12.9 years). Radiation morbidity included brain injury, retinopathy, optic neuropathy, keratopathy, and cataract. Overall and disease-free survivals were significantly better compared to historical treatments, but did not differ statistically from other modern approaches.

CONCLUSIONS:

Globe-preserving surgery with PBR, although imperfect, has a favorable long-term survival compared to other modern modalities, and offers a variable period of useful vision.

PMID:
30071211
DOI:
10.1016/j.ajo.2018.07.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center